LeMaitre Vascular (NASDAQ:LMAT) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, ValuEngine reports.

LMAT has been the topic of several other reports. BidaskClub lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Tuesday. Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a report on Thursday, February 21st. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, April 13th. Finally, Lake Street Capital raised their target price on LeMaitre Vascular to $27.00 and gave the stock a “hold” rating in a report on Wednesday, February 20th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $33.29.

LeMaitre Vascular stock opened at $27.24 on Thursday. The stock has a market cap of $538.52 million, a P/E ratio of 32.43, a P/E/G ratio of 2.87 and a beta of 1.15. LeMaitre Vascular has a 52 week low of $21.79 and a 52 week high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, February 19th. The medical instruments supplier reported $0.24 EPS for the quarter, hitting the consensus estimate of $0.24. The firm had revenue of $28.39 million for the quarter, compared to analyst estimates of $26.06 million. LeMaitre Vascular had a return on equity of 17.71% and a net margin of 21.73%. Analysts predict that LeMaitre Vascular will post 0.84 EPS for the current year.

In other LeMaitre Vascular news, insider Trent G. Kamke sold 16,604 shares of the firm’s stock in a transaction that occurred on Friday, February 22nd. The stock was sold at an average price of $29.63, for a total value of $491,976.52. Following the sale, the insider now directly owns 19,857 shares of the company’s stock, valued at $588,362.91. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 20.30% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of LMAT. BlackRock Inc. grew its holdings in LeMaitre Vascular by 4.9% in the third quarter. BlackRock Inc. now owns 2,545,148 shares of the medical instruments supplier’s stock valued at $98,599,000 after purchasing an additional 119,694 shares during the period. Vanguard Group Inc grew its holdings in LeMaitre Vascular by 5.8% in the third quarter. Vanguard Group Inc now owns 1,208,742 shares of the medical instruments supplier’s stock valued at $46,826,000 after purchasing an additional 66,427 shares during the period. Vanguard Group Inc. grew its holdings in LeMaitre Vascular by 5.8% in the third quarter. Vanguard Group Inc. now owns 1,208,742 shares of the medical instruments supplier’s stock valued at $46,826,000 after purchasing an additional 66,427 shares during the period. Conestoga Capital Advisors LLC grew its holdings in LeMaitre Vascular by 4.1% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,673,131 shares of the medical instruments supplier’s stock valued at $39,553,000 after purchasing an additional 66,131 shares during the period. Finally, Summit Creek Advisors LLC grew its holdings in LeMaitre Vascular by 14.9% in the fourth quarter. Summit Creek Advisors LLC now owns 336,409 shares of the medical instruments supplier’s stock valued at $7,953,000 after purchasing an additional 43,595 shares during the period. 76.52% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: What is a capital gain?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.